Dexmedetomidine an Effective Drug in Reducing Anesthetic Requirements in External Dacrocystorhinostomy (DCR) Patients

Phase 1

Recruiting

• Conditions: Patients Undergoing External Dacrocystorhinostomy Operations; Assess Decreased Anesthetic Requirements Intraoperative
• Interventions: Drug: Dexmedetomidine Hydrochloride

• Registration Number: NCT06808295
• Lead Sponsor: Research Institute of Ophthalmology, Egypt

Brief Summary

Assessing the intra and postoperative hemodynamic stability in patients undergoing external dacrocystorhinostomy under general anesthesia using Dexmedetomidine as a preoperative sedation compared to traditional technique with intraoperative analgesia and assessing decreased anesthetic requirements intra and postoperative

Detailed Description

Dexmedetomidine is a highly selective alpha 2 adrenoceptor agonist, having characteristics of natural sleep like sedation, can reduce pain intensity and opioid consumption without influencing the time of recovery from general anesthesia

Study Timeline

• Study Start: 2024-04-16
• Study First Submitted: 2024-12-14
• Status Verified: 2025-01
• Study First Submitted QC: 2025-01-31
• Last Update Submitted: 2025-01-31
• Study First Posted: 2025-02-05
• Last Update Posted: 2025-02-05
• Primary Completion: 2025-04-20
• Study Completion: 2025-05

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

patients of both sexes 16 years to 75 years of age ASA (American society of Anesthesiologists) I-III

Exclusion Criteria

• Pediatric age group
• ASA more than III

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Dexmedetomidine	Dexmedetomidine Hydrochloride	Dexmedetomidine 0.25 microgram per kilogram is used in Dacrocystorhinostomy patients 20 minutes before induction of general anesthesia

Primary Outcome Measures

Name	Time	Method
Maintained hemodynamic values while reducing the anesthetic requirements	from 20 minutes after administering the drug till 2 hours after full recovery	Measuring the heart rate and the blod pressure every 5 minutes intraoperative and for half an hour postoperative to assess hemodynamic stability

Secondary Outcome Measures

Name	Time	Method
Delerium	from 20 minutes after administering the drug till 2 hours after full recovery	Reducing postoperative delirium in elderly patients

Trial Locations

Locations (1)

Research Institute of Ophthalmolgy; 🇪🇬 Giza, Egypt